Antibody-Drug Conjugates Landscape, Challenges and Opportunities: iBET Welcomes Dr. John Lambert
Antibody-drug conjugates: Design, Developing Trends and Future Prospects
On December 3-4, iBET had the pleasure of hosting Dr. John M. Lambert, Honorary Professor at Queen’s University, Belfast (UK) and Consultant/Scientific Advisor in Cambridge, Massachusetts (USA) for two days of meaningful discussions and knowledge exchange.
Dr. John Lambert is widely recognized as one of the pioneers and leading experts of antibody-drug conjugates (ADCs) technology, with decades of experience shaping this innovative field.
ADCs combine the targeting precision of monoclonal antibodies with cytotoxic drugs, enabling the selective delivery of anti-cancer agents to tumor cells while minimizing damage to healthy tissues: a promising approach to improve both efficacy and safety in cancer therapy.
During his visit, Dr. Lambert met with iBET’s researchers to exchange knowledge in protein biophysics, bioanalytics, advanced cell models, technologies for gene therapy, and bioengineering of vaccines and cell-based therapies, discussing challenges and opportunities in ADCs R&D.
Group photo featuring Dr. John Lambert with some of the iBET scientists that attended the two-day visit.
He also delivered a seminar titled “Antibody-drug conjugates (ADCs): Design, Developing Trends and Future Prospects”, within the iNOVA4Health R&D unit. He shared key insights learned over several decades of experience, including factors critical to the success of ADCs, cross-roads in current technologies, and future directions for this class of anti-cancer medicines.
Dr. John Lambert presenting on current challenges and opportunities in ADCs to the iNOVA4Health research community.
Dr. John Lambert’s pioneering work dates to 1981, when he joined the Dana-Farber Cancer Institute at Harvard Medical School as one of the first scientists working on the ImmunoGen-funded programs to develop ADCs and immunotoxins, efforts that ultimately led to several approved anti-cancer therapies.
iBET acknowledges Dr. Lambert for his meaningful perspectives and looks forward to building on these discussions and advancing innovation in ADCs research.
